<DOC>
	<DOC>NCT02014740</DOC>
	<brief_summary>The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be associated with poor sugar control. Liraglutide is an injectable prescription medicine that can improve blood sugar control in adults with type 2 diabetes.</brief_summary>
	<brief_title>Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes, as defined by ADA criteria HbA1c &lt; 8% measured at least 1 month prior to this study BMI ≥27 kg/m2 Pretreatment with Metformin Age &gt; 18 and &lt; 65 years old • Known contraindications to Liraglutide, such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of MEN, in accordance with risks and safety information included in the latest updated Prescribing Information for Victoza® Type 1 diabetes, as defined by American Diabetes Association (ADA) criteria Insulin dependent or treated type 2 diabetes Current use of other injectable incretins History of diabetes ketoacidosis Advanced Chronic Kidney Disease, as defined by Glomerular Filtration Rate (GFR) &lt; 30 mL/min/1.73m2 Clinical signs or symptoms of New York Heart Association (NYHA) class IIIIV heart failure Clinical or laboratory evidences of chronic active liver diseases Acute or chronic infective diseases Cancer or chemotherapy Current use of systemic corticosteroids or in the 3 months prior this study Known or suspected allergy to Liraglutide, excipients, or related products Pregnant, breastfeeding or the intention of becoming pregnant Females of childbearing potential who are not using adequate contraceptive methods</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Epicardial fat</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Obesity</keyword>
	<keyword>GLP-1 analogs</keyword>
</DOC>